UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

The Lancet (British edition), 2011, Vol.377 (9759), p.42-51

2011

Volltextzugriff (PDF)

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Journal of clinical oncology, 2019-11, Vol.37 (31), p.JCO1901073-2824

2019

Volltextzugriff (PDF)

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

Clinical lymphoma, myeloma and leukemia, 2020-08, Vol.20 (8), p.509-518

2020

Volltextzugriff (PDF)

Positron Emission Tomography–Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants

Journal of clinical oncology, 2011-08, Vol.29 (23), p.3194-3200

2011

Volltextzugriff (PDF)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

Haematologica (Roma), 2022-01, Vol.107 (1), p.321-325

2022

Volltextzugriff (PDF)

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

Clinical hematology international, 2023-03, Vol.5 (1), p.43-51

2023

Volltextzugriff (PDF)

Formalising multidisciplinary peer review: developing a haematological malignancy‐specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence‐based clinical practice

Internal medicine journal, 2017-05, Vol.47 (5), p.542-548

2017

Volltextzugriff (PDF)

Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study

American journal of hematology, 2016-04, Vol.91 (4), p.410-415

2016

Volltextzugriff (PDF)

A Novel Case of Symptomatic BK Viraemia in a Patient Undergoing Treatment for Hodgkin Lymphoma

Case reports in infectious diseases, 2014-01, Vol.2014 (2014), p.1-4

2014

Volltextzugriff (PDF)

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-08, Vol.375 (8), p.754-766

2016

Volltextzugriff (PDF)

2226 CANOMAD: a case report

BMJ neurology open, 2022-08, Vol.4 (Suppl 1), p.A19-A19

2022

Volltextzugriff (PDF)

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.10174-10176

2022

Volltextzugriff (PDF)

The Effect of Daratumumab, Lenalidomide, Dexamethasone (DRd) on Peripheral Blood Stem Cell Mobilisation (PBSC)

Blood, 2021-11, Vol.138 (Supplement 1), p.3884-3884

2021

Volltextzugriff (PDF)

Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.1665-1665

2021

Volltextzugriff (PDF)

A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood, 2021-11, Vol.138 (Supplement 1), p.2755-2755

2021

Volltextzugriff (PDF)

Fragmented diagnoses

Pathology, 2016-02, Vol.48, p.S35-S35

2016

Volltextzugriff (PDF)

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Blood, 2018-11, Vol.132 (Supplement 1), p.1986-1986

2018

Volltextzugriff (PDF)

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma

European journal of clinical pharmacology, 2022-12, Vol.78 (12), p.1911-1921

2022

Volltextzugriff (PDF)

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS8055-TPS8055

2021

Volltextzugriff (PDF)

CGRA12: SURVIVING THE GREEN NEUTROPHILIC INCLUSIONS OF IMPENDING DEATH

Internal medicine journal, 2016-09, Vol.46 (S4), p.32-33

2016

Volltextzugriff (PDF)

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.1955-1955

2018

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(44)
Bücher
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(11)
Female
(10)
Middle Aged
(10)
Hematology
(9)
Male
(9)
Adult
(8)
Aged
(8)
Aged, 80 And Over
(5)
General & Internal Medicine
(4)
Medicine, General & Internal
(4)
Multiple Myeloma
(4)
Oncology
(4)
Patients
(4)
Survival
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Biological And Medical Sciences
(3)
Clinical Trials
(3)
Disease-Free Survival
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Positron Emission Tomography–Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants

Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

Formalising multidisciplinary peer review: developing a haematological malignancy‐specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence‐based clinical practice

Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study

A Novel Case of Symptomatic BK Viraemia in a Patient Undergoing Treatment for Hodgkin Lymphoma

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

2226 CANOMAD: a case report

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

The Effect of Daratumumab, Lenalidomide, Dexamethasone (DRd) on Peripheral Blood Stem Cell Mobilisation (PBSC)

Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Fragmented diagnoses

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand

CGRA12: SURVIVING THE GREEN NEUTROPHILIC INCLUSIONS OF IMPENDING DEATH

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Suchergebnisse filtern